Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844973 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients
A Phase 1 study of Psoriasis, sponsored by Maruho North America.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01844973: Completed Phase 1 study of Psoriasis, sponsored by Maruho North America.
NCT01844973 is a Phase 1 study of Psoriasis that has completed, run by Maruho North America. The registered enrollment target is 30 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01844973, a Phase 1 study of Psoriasis, has completed, sponsored by Maruho North America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the pharmacokinetics and safety of M518101 in male and female plaque psoriasis patients.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG M518101
Study Locations (1)
California
- Orenge County Research Center - Tustin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
What the finished NCT01844973 record still lists
NCT01844973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT01844973 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01844973 about?
NCT01844973 is a clinical study titled "Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients". This study is to evaluate the pharmacokinetics and safety of M518101 in male and female plaque psoriasis patients.
What is the current status of trial NCT01844973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-04. Estimated completion is 2013-08.
What conditions does trial NCT01844973 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01844973?
The interventions under investigation include: Vehicle (DRUG), M518101 (DRUG).
Who is sponsoring clinical trial NCT01844973?
This trial is sponsored by Maruho North America, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01844973 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01844973's enrollment target sits among peer trials
30 95th of 125 higher than 26 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia